Advanced in Hyperlipidemia Type 3

Robert A. Hegele

London, ON, CA 
Advanced in Hyperlipidemia Type 3
London, ON, CA 
OverviewLocationsClinical Research

Overview

Robert Hegele practices in London, Canada. Hegele is rated as an Advanced expert by MediFind in the treatment of Hyperlipidemia Type 3. Their top areas of expertise are Familial Hypertriglyceridemia, High Cholesterol, Familial Hypercholesterolemia, and Homozygous Familial Hypercholesterolemia (HoFH).

Their clinical research consists of co-authoring 573 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Hyperlipidemia Type 3.

Locations

London, ON, Canada
Other Locations
ON, Canada
Toronto, ON, Canada
Hamilton, ON, Canada
Ottawa, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 2
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 3
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: November 07, 2024
Intervention Type: Drug
Study Phase: Phase 2
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

566 Total Publications

A Personalized Medicine Approach is Best for Patients with Homozygous Familial Hypercholesterolemia.
A Personalized Medicine Approach is Best for Patients with Homozygous Familial Hypercholesterolemia.
Journal: Medical research archives
Published: September 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hegele's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 15 Distinguished Conditions
View All 13 Advanced Conditions
View All 70 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile